-
Something wrong with this record ?
Investigation of flexibility of neuraminidase 150-loop using tamiflu derivatives in influenza A viruses H1N1 and H5N1
V. Zima, CB. Albiñana, K. Rojíková, J. Pokorná, P. Pachl, P. Řezáčová, J. Hudlicky, V. Navrátil, P. Majer, J. Konvalinka, M. Kožíšek, A. Machara,
Bioorganic & medicinal chemistry.
2019 ;
27 (13) :
2935-2947.
[pub] 20190517
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
Persistent link
https://www.medvik.cz/link/bmc20025788
- MeSH
- Humans MeSH
- Neuraminidase pharmacology therapeutic use MeSH
- Oseltamivir pharmacology therapeutic use MeSH
- Influenza A Virus, H1N1 Subtype pathogenicity MeSH
- Influenza A Virus, H5N1 Subtype pathogenicity MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
This study focuses on design, synthesis and in vitro evaluation of inhibitory potency of two series of sialylmimetic that target an exosite ("150-cavity") adjacent to the active site of influenza neuraminidases from A/California/07/2009 (H1N1) pandemic strain and A/chicken/Nakorn-Patom/Thailand/CU-K2-2004 (H5N1). The structure-activity analysis as well as 3-D structure of the complex of parental compound with the pandemic neuraminidase p09N1 revealed high flexibility of the 150-cavity towards various modification of the neuraminidase inhibitors. Furthermore, our comparison of two methods for inhibition constant determination performed at slightly different pH values suggest that the experimental conditions of the measurement could dramatically influence the outcome of the analysis in the compound-dependent manner. Therefore, previously reported Ki values determined at non-physiological pH should be carefully scrutinized.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025788
- 003
- CZ-PrNML
- 005
- 20201222154105.0
- 007
- ta
- 008
- 201125s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.bmc.2019.05.024 $2 doi
- 035 __
- $a (PubMed)31128993
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Zima, Václav $u Department of Organic Chemistry, Faculty of Science, Charles University, Hlavova 8, 128 00 Prague 2, Czech Republic; Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 245 10
- $a Investigation of flexibility of neuraminidase 150-loop using tamiflu derivatives in influenza A viruses H1N1 and H5N1 / $c V. Zima, CB. Albiñana, K. Rojíková, J. Pokorná, P. Pachl, P. Řezáčová, J. Hudlicky, V. Navrátil, P. Majer, J. Konvalinka, M. Kožíšek, A. Machara,
- 520 9_
- $a This study focuses on design, synthesis and in vitro evaluation of inhibitory potency of two series of sialylmimetic that target an exosite ("150-cavity") adjacent to the active site of influenza neuraminidases from A/California/07/2009 (H1N1) pandemic strain and A/chicken/Nakorn-Patom/Thailand/CU-K2-2004 (H5N1). The structure-activity analysis as well as 3-D structure of the complex of parental compound with the pandemic neuraminidase p09N1 revealed high flexibility of the 150-cavity towards various modification of the neuraminidase inhibitors. Furthermore, our comparison of two methods for inhibition constant determination performed at slightly different pH values suggest that the experimental conditions of the measurement could dramatically influence the outcome of the analysis in the compound-dependent manner. Therefore, previously reported Ki values determined at non-physiological pH should be carefully scrutinized.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a virus chřipky A, podtyp H1N1 $x patogenita $7 D053118
- 650 _2
- $a virus chřipky A, podtyp H5N1 $x patogenita $7 D053124
- 650 _2
- $a neuraminidasa $x farmakologie $x terapeutické užití $7 D009439
- 650 _2
- $a oseltamivir $x farmakologie $x terapeutické užití $7 D053139
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Albiñana, Carlos Berenguer $u Department of Organic Chemistry, Faculty of Science, Charles University, Hlavova 8, 128 00 Prague 2, Czech Republic; Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 700 1_
- $a Rojíková, Kateřina $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 166 10 Prague 6, Czech Republic; First Faculty of Medicine, Charles University, Kateřinská 1660/32, 121 08, Prague, Czech Republic.
- 700 1_
- $a Pokorná, Jana $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 700 1_
- $a Pachl, Petr $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 700 1_
- $a Řezáčová, Pavlína $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 166 10 Prague 6, Czech Republic; Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Vídeňská 1083, 140 00 Prague 4, Czech Republic.
- 700 1_
- $a Hudlicky, Jason $u Department of Organic Chemistry, Faculty of Science, Charles University, Hlavova 8, 128 00 Prague 2, Czech Republic; Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 700 1_
- $a Navrátil, Václav $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 700 1_
- $a Majer, Pavel $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 700 1_
- $a Konvalinka, Jan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 166 10 Prague 6, Czech Republic; Department of Biochemistry, Faculty of Science, Charles University, Hlavova 8, 128 00 Prague 2, Czech Republic.
- 700 1_
- $a Kožíšek, Milan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 700 1_
- $a Machara, Aleš $u Department of Organic Chemistry, Faculty of Science, Charles University, Hlavova 8, 128 00 Prague 2, Czech Republic; Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 166 10 Prague 6, Czech Republic. Electronic address: ales.machara@uochb.cas.cz.
- 773 0_
- $w MED00000769 $t Bioorganic & medicinal chemistry $x 1464-3391 $g Roč. 27, č. 13 (2019), s. 2935-2947
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31128993 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222154101 $b ABA008
- 999 __
- $a ok $b bmc $g 1599933 $s 1116474
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 27 $c 13 $d 2935-2947 $e 20190517 $i 1464-3391 $m Bioorganic & medicinal chemistry $n Bioorg Med Chem $x MED00000769
- LZP __
- $a Pubmed-20201125
